Dexmedetomidine in success of nerve block

Evaluation of effect of adding Dexmedetomidine to Lidocaine in success of inferior alveolar nerve block in patients with asymptomatic irreversible pulpitis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150815023620N8

Enrollment

Registered

2018-07-08

Start date

2017-11-22

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asymptomatic irreversible pulpitis. Pulpitis

Interventions

Intervention 1: intervention group:Dexmedetomidine 0.5µ\kg (0.4ml) + Lidocaine 1.55%(1.4ml) Dexmedetomidine is manufactured by Hospira. Each patient in Intervention group recieves an Inferior Alveolar

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having a tooth with asymptomatic irreversible pulpitis ASA Cl I,II Age (between 18-65 ys )

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Smoking Addiction taking psychologic drugs taking sedatives/analgesics in last 24h before treatment Having allergies to anesthetics systemic disease

Design outcomes

Primary

Measure	Time frame
Inferior Alveolar Nerve blockage. Timepoint: during endodontic treatment. Method of measurement: visual analogue scale.;Feeling of tingling. Timepoint: 10min after intervention. Method of measurement: Electric pulp tester.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirabbas Moshari

Islamic Azad University

amirabbas.moshari@gmail.com+98 21 2281 8161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026